FDA Approves New Intravenous Monkeypox Drug Treatment From PFIZER-Linked SIGA Technologies

In 2019, a company called SIGA Technologies announced a promotion agreement for TPOXX, its smallpox/monkeypox drug, with Meridian Medical Technologies.

Guess who owns Meridian?

Pfizer.

Today, the FDA approved SIGA's drug.

Pfizer scores again.https://t.co/AUj9aFQWex

— Jordan Schachtel @ dossier.substack.com (@JordanSchachtel) May 19, 2022

Pfizer is apparently at it again, conveniently hitting another grand slam with another perfectly timed drug release for the latest viral outbreak sweeping the west – monkeypox. 

After hitting it out of the park with their experimental mRNA Covid vaccine – typically what would be considered a once-in-a-lifetime development that’s cashing the company out to a tune of $1,000 per second – it seems like a long stretch that Pfizer would be involved in the ‘cure’ for the new outbreak, but hey, they apparently pulled it off. 

On Thursday, the US Food and Drug Administration (FDA) announced that it had approved the company’s intravenous version of TPOXX® (tecovirimat) for use in the US to treat monkeypox. The new drug was created by SIGA Technologies, which formed a partnership related to the drug with Meridian Medical Technologies in 2019.